Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma

被引：0

作者：

Satoshi Yamasaki

Dai Chihara

Sung-Won Kim

Koji Izutsu

Kouji Iwato

Takahiro Fukuda

Naoyuki Uchida

Itsuto Amano

Hideyuki Nakazawa

Junya Kuroda

Hisako Hashimoto

Tatsuo Ichinohe

Yoshinobu Kanda

Yoshiko Atsuta

Junji Suzumiya

Ritsuro Suzuki

机构：

[1] National Hospital Organization Kyushu Medical Center,Department of Hematology and Clinical Research Institute

[2] The University of New Mexico,Department of Internal Medicine

[3] National Cancer Center Hospital,Division of Hematopoietic Stem Cell Transplantation

[4] Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital,Department of Hematology

[5] Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital,Department of Hematology

[6] Nara Medical University Hospital,Department of Respiratory, Allergy, and Hematology

[7] Shinshu University School of Medicine,Division of Hematology, Department of Internal Medicine

[8] Kyoto Prefectural University of Medicine,Division of Hematology and Oncology, Department of Medicine

[9] Kobe General Hospital and Institute of Biomedical Research and Innovation,Department of Hematology and Cell therapy

[10] Hiroshima University,Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine

[11] Jichi Medical University,Division of Hematology, Saitama Medical Center

[12] Nagoya University Graduate School of Medicine and Japanese Data Center for Hematopoietic Cell Transplantation,Department of Healthcare Administration

[13] Shimane University Hospital,Department of Oncology and Hematology

来源：

Annals of Hematology | 2018年 / 97卷

关键词：

Mantle cell lymphoma; Autologous hematopoietic cell transplantation; Allogeneic hematopoietic cell transplantation relapsed or refractory;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Rituximab has been shown to improve outcomes in patients with B-cell lymphoma. However, patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) still have a poor prognosis, and the choice between high-dose therapy with autologous hematopoietic cell transplantation (HCT) and allogeneic HCT remains controversial in these patients. We retrospectively analyzed the risk factors for outcomes in 162 R/R MCL patients who received autologous (n = 111) or allogeneic (n = 51) HCT between 2004 and 2014. The median overall survival (OS) rates were 48 and 65 months in the autologous and allogeneic HCT groups, respectively (P = 0.20). Significant risk factors for overall survival in R/R MCL patients after autologous HCT were > 60 years of age at HCT (P = 0.017), higher score of HCT-specific comorbidity index at HCT (P = 0.033), and receiving MCEC (ranimustine + carboplatin + etoposide + cyclophosphamide) regimen (P = 0.017), while higher performance status at HCT (P = 0.011) and longer interval from diagnosis to HCT (P = 0.0054) were risk factors after allogeneic HCT. Strategies that carefully select R/R MCL patients for autologous HCT may allow the identification of individuals suitable for allogeneic HCT.

引用

页码：1445 / 1452

页数：7

共 305 条

[1]

Dreyling M(2005)Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network Blood 105 2677-2684

[2]

Lenz G(2016)The 2016 revision of the World Health Organization classification of lymphoid neoplasms Blood 127 2375-2390

[3]

Hoster E(2007)Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system Int J Hematol 86 269-274

[4]

Van Hoof A(2016)Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data) Int J Hematol 103 3-10

[5]

Gisselbrecht C(1995)1994 consensus conference on acute GVHD grading Bone Marrow Transplant 15 825-828

[6]

Schmits R(2005)National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report Biol Blood Marrow Transplant 11 945-956

[7]

Metzner B(2013)Investigation of the freely available easy-to-use software 'EZR' for medical statistics Bone Marrow Transplant 48 452-458

[8]

Truemper L(2009)Reduced intensity conditioning regimen workshop: defining the dose spectrum-report of a workshop convened by the center for international blood and marrow transplant research Biol Blood Marrow Transplant 15 367-369

[9]

Reiser M(2015)The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma Leukemia 29 464-473

[10]

Steinhauer H(2013)Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation Biol Blood Marrow Transplant 19 1403-1406

← 1 2 3 4 5 6 7 8 9 10 →